Liposomal iron achieves a partial correction of transferrin saturation, with no significant effect on iron storage and hemoglobin, in patients with NDD-CKD.
Within one month of treatment, anti-VEGF therapy improves anatomic and visual outcomes among eyes with stage 3 and 4 proliferative sickle cell retinopathy.